At close: January 8 at 4:00:01 PM EST
Pre-Market: 6:05:52 AM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 14 | 13 |
| Avg. Estimate | 0.39 | 0.51 | 1.89 | 2.2 |
| Low Estimate | 0.36 | 0.48 | 1.78 | 1.99 |
| High Estimate | 0.4 | 0.54 | 2.11 | 2.4 |
| Year Ago EPS | 0.4 | 0.48 | 1.77 | 1.89 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 14 | 13 |
| Avg. Estimate | 286.03M | 318.04M | 1.22B | 1.34B |
| Low Estimate | 282.56M | 312.6M | 1.21B | 1.3B |
| High Estimate | 289.54M | 325.3M | 1.24B | 1.37B |
| Year Ago Sales | 272.6M | 303.43M | 1.16B | 1.22B |
| Sales Growth (year/est) | 4.93% | 4.82% | 5.58% | 9.27% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | 0.41 | 0.46 | 0.49 | 0.38 |
| EPS Actual | 0.4 | 0.48 | 0.49 | 0.42 |
| Difference | -0.01 | 0.02 | -0 | 0.04 |
| Surprise % | -3.12% | 5.27% | -0.96% | 10.24% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0.39 | 0.51 | 1.89 | 2.2 |
| 7 Days Ago | 0.39 | 0.51 | 1.89 | 2.2 |
| 30 Days Ago | 0.38 | 0.51 | 1.89 | 2.2 |
| 60 Days Ago | 0.38 | 0.52 | 1.87 | 2.18 |
| 90 Days Ago | 0.38 | 0.52 | 1.87 | 2.18 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 4 | -- | -- | -- |
| Up Last 30 Days | 4 | 1 | 1 | 1 |
| Down Last 7 Days | 4 | 1 | 1 | 1 |
| Down Last 30 Days | 4 | 1 | 1 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| TECH | -3.58% | 7.20% | 7.01% | 15.96% |
| S&P 500 | 8.82% | 11.58% | 14.01% | 13.43% |
Upgrades & Downgrades
| Maintains | Scotiabank: Sector Outperform to Sector Outperform | 10/31/2024 |
| Maintains | Baird: Outperform to Outperform | 10/31/2024 |
| Reiterates | Benchmark: Buy to Buy | 8/13/2024 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 8/8/2024 |
| Maintains | Baird: Outperform to Outperform | 8/8/2024 |
| Downgrade | Citigroup: Buy to Neutral | 5/22/2024 |
Related Tickers
INCY Incyte Corporation
73.13
-0.08%
UTHR United Therapeutics Corporation
366.61
+1.18%
ALNY Alnylam Pharmaceuticals, Inc.
240.55
+1.95%
NUVL Nuvalent, Inc.
78.25
-2.33%
BPMC Blueprint Medicines Corporation
90.63
-3.96%
PTCT PTC Therapeutics, Inc.
45.04
+0.96%
GMAB Genmab A/S
22.19
+0.05%
RPRX Royalty Pharma plc
26.20
+0.61%
ASND Ascendis Pharma A/S
134.43
-2.08%
BBIO BridgeBio Pharma, Inc.
29.45
+2.08%